TrialBlood cancer journal2026

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.

Natalia Timofeeva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.